These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 26389682)

  • 41. Management of behavioral and psychological symptoms in people with Alzheimer's disease: an international Delphi consensus.
    Kales HC; Lyketsos CG; Miller EM; Ballard C
    Int Psychogeriatr; 2019 Jan; 31(1):83-90. PubMed ID: 30068400
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interventions for Neuropsychiatric Symptoms in Neurocognitive Impairment Due to Alzheimer's Disease: A Review of the Literature.
    McClam TD; Marano CM; Rosenberg PB; Lyketsos CG
    Harv Rev Psychiatry; 2015; 23(5):377-93. PubMed ID: 26332220
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lithium Treatment for Agitation in Alzheimer's disease (Lit-AD): Clinical rationale and study design.
    Devanand DP; Strickler JG; Huey ED; Crocco E; Forester BP; Husain MM; Vahia IV; Andrews H; Wall MM; Pelton GH
    Contemp Clin Trials; 2018 Aug; 71():33-39. PubMed ID: 29859917
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales.
    Tariot PN; Loy R; Ryan JM; Porsteinsson A; Ismail S
    Adv Drug Deliv Rev; 2002 Dec; 54(12):1567-77. PubMed ID: 12453674
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacotherapy for behavioral and psychological symptoms of dementia in the elderly.
    Beier MT
    Am J Health Syst Pharm; 2007 Jan; 64(2 Suppl 1):S9-17; quiz S24-5. PubMed ID: 17215476
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial.
    Schneider LS; Frangakis C; Drye LT; Devanand DP; Marano CM; Mintzer J; Mulsant BH; Munro CA; Newell JA; Pawluczyk S; Pelton G; Pollock BG; Porsteinsson AP; Rabins PV; Rein L; Rosenberg PB; Shade D; Weintraub D; Yesavage J; Lyketsos CG;
    Am J Psychiatry; 2016 May; 173(5):465-72. PubMed ID: 26771737
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial.
    Ehrhardt S; Porsteinsson AP; Munro CA; Rosenberg PB; Pollock BG; Devanand DP; Mintzer J; Rajji TK; Ismail Z; Schneider LS; Baksh SN; Drye LT; Avramopoulos D; Shade DM; Lyketsos CG;
    Alzheimers Dement; 2019 Nov; 15(11):1427-1436. PubMed ID: 31587995
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy.
    Salzman C; Jeste DV; Meyer RE; Cohen-Mansfield J; Cummings J; Grossberg GT; Jarvik L; Kraemer HC; Lebowitz BD; Maslow K; Pollock BG; Raskind M; Schultz SK; Wang P; Zito JM; Zubenko GS
    J Clin Psychiatry; 2008 Jun; 69(6):889-98. PubMed ID: 18494535
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence.
    Franco KN; Messinger-Rapport B
    J Am Med Dir Assoc; 2006 Mar; 7(3):201-2. PubMed ID: 16503315
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacologic management of neuropsychiatric symptoms of Alzheimer disease.
    Herrmann N; Lanctôt KL
    Can J Psychiatry; 2007 Oct; 52(10):630-46. PubMed ID: 18020111
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease.
    Trzepacz PT; Cummings J; Konechnik T; Forrester TD; Chang C; Dennehy EB; Willis BA; Shuler C; Tabas LB; Lyketsos C
    Int Psychogeriatr; 2013 May; 25(5):707-19. PubMed ID: 23257314
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Citalopram for agitation in Alzheimer's disease: design and methods.
    Drye LT; Ismail Z; Porsteinsson AP; Rosenberg PB; Weintraub D; Marano C; Pelton G; Frangakis C; Rabins PV; Munro CA; Meinert CL; Devanand DP; Yesavage J; Mintzer JE; Schneider LS; Pollock BG; Lyketsos CG;
    Alzheimers Dement; 2012; 8(2):121-30. PubMed ID: 22301195
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Pharmacological treatment of behavioral symptoms in dementia patients].
    Gabryelewicz T
    Przegl Lek; 2014; 71(4):215-20. PubMed ID: 25141581
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of psychotropic agents to treat agitation and aggression in Brazilian patients with Alzheimer's disease: A naturalistic and multicenter study.
    Oliveira LF; Camargos EF; Martini LLL; Machado FV; Novaes MRCG
    Psychiatry Res; 2021 Jan; 295():113591. PubMed ID: 33271491
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antipsychotic treatment patterns in Alzheimer's disease patients with agitation: a cohort study using the UK clinical practice research datalink.
    Tran CT; Bøg M; Collings SL; Johnson M; Qizilbash N; Lind S; Baker RA; Jørgensen KT
    Curr Med Res Opin; 2022 Mar; 38(3):409-416. PubMed ID: 35068266
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Natural and Synthetic Cannabinoids for Agitation and Aggression in Alzheimer's Disease: A Meta-Analysis.
    Ruthirakuhan M; Lanctôt KL; Vieira D; Herrmann N
    J Clin Psychiatry; 2019 Jan; 80(2):. PubMed ID: 30753761
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Management of neuropsychiatric symptoms in dementia.
    Devanand DP
    Curr Opin Neurol; 2023 Oct; 36(5):498-503. PubMed ID: 37639488
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Systematic Review of Clinical Studies on the Effect of Psychoactive Cannabinoids in Psychiatric Conditions in Alzheimer Dementia.
    Paunescu H; Dima L; Ghita I; Coman L; Ifteni PI; Fulga I; Coman OA
    Am J Ther; 2020; 27(3):e249-e269. PubMed ID: 32118591
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Psychopharmacology of noncognitive abnormal behaviors in Alzheimer's disease.
    Raskind MA
    J Clin Psychiatry; 1998; 59 Suppl 9():28-32. PubMed ID: 9720484
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treating behavioral and psychological symptoms in patients with psychosis of Alzheimer's disease using risperidone.
    Rabinowitz J; Katz I; De Deyn PP; Greenspan A; Brodaty H
    Int Psychogeriatr; 2007 Apr; 19(2):227-40. PubMed ID: 16879763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.